Summary
The angiotensin converting enzyme (ACE) inhibitors are a group of effective drugs with a unique mechanism of action. These drugs have proven to be useful for hypertension and congestive heart failure. Early clinical trials of captopril used doses that are now known to be inappropriately high, and dose-related adverse effects were observed frequently. The recognition that lower doses are effective has reduced the incidence of adverse reactions and resulted in improved patient tolerance. When patients are properly selected and correctable risk factors are removed, serious side effects are uncommon. Unfortunately, the early reputation of nephrotoxicity persists, as does the belief that significant blood dyscrasias, endocrine effects and rash are serious risks for the average patient.
After wide use of captopril, enalapril and lisinopril, and investigational trials of nearly a dozen newer agents, a sufficiency of clinical observation, experimental evidence and accurate postmarketing recording of events is accumulating to allow insight into the major toxicities with regard to more intelligent patient selection, more rational dosing and proper identification of risk factors.
The most common adverse reactions are cough and skin rash. It appears that the agents are generally not cross-reactive with regard to skin rash, although it is not clear whether this effect is drug-specific or class-specific with regard to cough.
Statistically but not clinically significant lowering of haemoglobin and hematocrit is common; these effects are inconsequential in most patients. Neutropenia, once thought to be prevalent, now appears to be so only in patients with autoimmune or collagen-vascular disease; the majority of patients outside these groups are at low risk.
Hyperkalaemia is a frequent occurrence. This should not be surprising in view of the effect of the ACE inhibitors on plasma aldosterone. When dietary potassium intake is regulated and sources of altered potassium excretion are identified, hyperkalaemia is seldom a serious problem. Identification of sodium and water deficits allows correction before the drugs are started, and the frequency of hypotension and hyperkalaemia caused by the drugs is quite low if these factors are properly managed.
An unexpected finding emerging in recent years is the dry cough associated with ACE inhibitor therapy. Its mechanism is not definitely known. Nonsteroidal anti-inflammatory drugs may control this symptom in some patients.
The frequent observation of proteinuria in patients taking ACE inhibitors has gained notice and sometimes caused undue alarm. It is difficult to separate disease effects in diabetes and hypertension from true drug effects. Proteinuria may be only slightly more common with drug therapy than in the population of patients with these diseases who are not taking ACE inhibitors. The drugs now appear to be directly nephrotoxic only in rare cases. In many patient populations, they may even slow the advance of renal disease or be protective of renal function. Risk factors for the development of functional renal insufficiency have been identified and high risk patients can either avoid ACE inhibitor therapy or start at lower doses.
The drugs still cannot be recommended for use in pregnancy except in circumstances where they are the only means of managing life-threatening hypertension. ACE inhibitors appear to be safe and effective for severe childhood hypertension, but not in neonates.
The majority of clinical experience, especially postmarketing studies, has dealt with captopril and enalapril. Experience continues to accumulate with lisinopril, ramipiril, benazepril and other new agents, but to date these appear to be indistinguishable from enalapril in their side effect profiles.
The ACE inhibitors appear to be attractive choices for managing hypertension of all degrees, and congestive heart failure in all stages. With intelligent use, they offer a reasonably safe alternative to older therapies and may have significant advantages in well selected patients.
Similar content being viewed by others
References
Ackroyd JF. Thrombocytopenia and angiotensin converting enzyme inhibitors. British Medical Journal 298: 964, 1989
Anagnovstou A, Baranowski D, Pillay VKG, Kurtzman NA, Vercelotti G, et al. Effect of renin on extra-renal erythropoietin production. Journal of Laboratory and Clinical Medicine 88: 705–715, 1976
Andrejak M, Andrejak MT, Osterman G. Enalapril, captopril, and cough. Archives of Internal Medicine 148: 249, 1988
Arrequi A, Iverseb LL, Spokes EGS, Emson PC. Alterations in postmortem brain angiotensin-converting enzyme activity and some neuropeptides in Huntington’s disease. Advances in Neurology 23: 517–525, 1979
Biour M, LeJunne C, Hughes FC, Cheymol G. Diclofenac et toux induite par les inhibiteurs de l’enzyme de conversion. Thérapie 43: 121–122, 1988
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, et al. Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. British Medical Journal 293: 471–474, 1986
Boutroy MJ, Vert P. Captopril administration in pregnancy impairs fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet 2: 935–936, 1984
Brown RC, Turton CWG. Cough and angiotensin-converting enzyme inhibition. British Medical Journal (Clinical Research) 296: 1741, 1988
Broughton Pipkin F, Baker PN, Symonds EM. ACE inhibitors in pregnancy. Lancet 2: 96–97, 1989
Broughton Pipkin F, Turner SR, Symonds EM. Possible risk with captopril in pregnancy: some animal data. Lancet 1: 1256, 1980
Brunner HR, Laragh JH, Bair L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. New England Journal of Medicine 286: 441–447, 1972
Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension. American Journal of Medicine 55: 295–302, 1973
Bunner R, Waeber B, Nussberger J. Renal effects of converting enzyme inhibition. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S6–S14, 1987
Bucca C, Rolla G, Pinna G, Oliva A, Bugiani M. Hyperresponsiveness of the extrathoracic airway in patients with captopril-induced cough. Chest 98: 1133–1137, 1990
Cameron DI. Near fatal angioedema associated with captopril. Canadian Journal of Cardiology 6: 265–266, 1990
Captopril Collaborative Study Group. Does captopril cause renal damage in hypertensive patients? Lancet 1: 988–990, 1982
Carruthers SG. Severe coughing during captopril and enalapril therapy. Canadian Medical Association Journal 135: 217–218, 1986
Chin HL, Buchan DA. Severe angioedema after long-term use of an angiotensin converting enzyme inhibitor. Annals of Internal Medicine 112: 312–313, 1990
Christlieb AR, Gleason RE, Hickler RB, Lauler DP. Renin: a risk factor for cardiovascular disease? Annals of Internal Medicine 81: 7–13, 1974
Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, et al. Severe hypotension after first dose of enalapril in heart failure. British Medical Journal 291: 1309–1312, 1985
Cohen KR. Flushing induced by angiotensin converting enzyme inhibitor therapy. American Journal of Medicine 86: 358, 1989
Committee on Safety of Medicines. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. British Medical Journal 294: 91, 1987
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. New England Journal of Medicine 36: 1429–1435, 1987
Cook J, Daneman D, Spino M, Sochett E, Perlman K, et al. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. Journal of Pediatrics 117 (Suppl. 1, P1): 39–45, 1990
Coulter DM, Edwards IR. Cough associated with captopril and enalapril. British Medical Journal 294: 1521–1523, 1987
Cuniff C, Jones KL, Phillipson J, Benirschke K, Short S, et al. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. American Journal of Obstetrics and Gynecology 192: 187–189, 1990
DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Medical Toxicology 1: 122–141, 1986
Drucker CR, Johnson TM. Captopril glossopyrosis. Archives of Dermatology 125: 1437–1438, 1989
Duminy PC, Burger PT. Fetal abnormality associated with the use of captopril during pregnancy. South African Medical Journal 60: 805, 1981
Edwards IR, Coulter DM, Beasley DMG, Macintosh D. Captopril: 4 years of postmarketing surveillance of all patients in New Zealand. British Journal of Clinical Pharmacology 23: 529–536, 1987
Ellis A, Lishner M, Lang R, Ravid M. Agranulocytosis associated with enalapril. DICP — Annals of Pharmacotherapy 25: 461–462, 1991
Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiologica 40: 199–205, 1985
Federal Register (US) 44: 37434–37467, 1980
Feig PU, Rutan GH. Angiotensin converting enzyme inhibitors: the end of end-stage renal disease? Annals of Internal Medicine 111: 451–453, 1989
Ferguson RK, Vlasses PH, Irvin JD, Swanson BN, Lee RB. A comparative pilot study of enalapril, a new converting enzyme inhibitor and hydrochlorothiazide in essential hypertension. Journal of Clinical Pharmacology 22: 281–289, 1982
Fernere M, Lachkar H, Richard J-L, Bringer J, Orsetti A, et al. Captopril and insulin sensitivity. Annals of Internal Medicine 102: 134–135, 1985
Frank GJ. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects? Journal of Hypertension 7 (Suppl. 5): 517–522, 1989
Goldblatt J, Bryer A. Huntington’s disease: deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. British Medical Journal 294: 1659–1660, 1987
Grosbois B, Milton D, Beneton C, Jacomy D. Thrombocytopenia induced by angiotensin converting enzyme inhibition. British Medical Journal 298: 189–190, 1989
Guignard JP, Gouyon JB. Adverse effects of drugs on the immature kidney. Biology of the Neonate 53: 243–252, 1988
Heckerling PS. Enalapril and vulvovaginal pruritis. Annals of Internal Medicine 112: 879–890, 1990
Heeg JE, DeJong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney International 32: 78–83, 1987
Helgeland A, Strammen R, Hagelund CH, Tretli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. Lancet 1: 872–875, 1986
Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Annals of Internal Medicine 103: 222–223, 1985
Hume AL, Jack BW, Levinson P. Severe hyponatraemia: an association with lisinopril? DICP — Annals of Pharmacotherapy 24: 1169–1172, 1990
Ikeda T, Nakayama D, Gomi T, Sakurai J, Yamazaki T, et al. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52: 72–75, 1989
Ikram H. Arrhythmias, electrolytes, and ACE inhibitor therapy in the elderly. Gerontology 33 (Suppl. 1): 42–47, 1987
Inman WHW. Enalapril-induced cough. Lancet 2: 218, 1986
Inman WHW, Rawson NSB. Deafness with enalapril and prescription event monitoring. Lancet 1: 872, 1987
Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Speirs CJ. Postmarketing surveillance of enalapril I: results of prescription-event monitoring. British Medical Journal 297: 826–829, 1988
Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. American Journal of Medicine 80: 471–476, 1986
Jett GK. Captopril-induced angioedema. Annals of Emergency Medicine 13: 489–490, 1984
Johnson SA, Aurell M. Immunosuppressive action of captopril blocked by prostaglandin synthetase inhibitor. Lancet 1: 1005, 1981
Just PM. The positive association of cough with angiotensin converting enzyme inhibitors. Pharmacotherapy 9: 82–87, 1989
Kaler SG, Patrinos ME, Lambert GH, Myers TF, Karlman R, et al. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics 79: 431–436, 1987
Kallenberg CGM, van der Laan S, deZeeuw D. Captopril and the immune system. Lancet 2: 92, 1981
Katayama S, Inaba M, Maruno Y, Omoto A, Itabashi A, et al. Captopril-induced creatinine kinase elevations: a possible role of the sulfhydryl group. Hypertension 10: 234–236, 1987
Katz RA, Hood AF, Anhalt GJ. Pemphigus-like eruption from captopril. Archives of Dermatology 123: 20–21, 1987
Katzman PL, Henningsen NC, Fagher B, Thuylin T, Hulthén UL. Renal and endocrine effects of long-term converting enzyme inhibition as compared with calcium antagonism in essential hypertension. Journal of Cardiovascular Pharmacology 15: 360–364, 1990
Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, et al. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Annals of Internal Medicine 111: 503–516, 1989
Kreft-Jais C, Plouin PF, Tchobroutsky C, Boutroy J. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. British Journal of Obstetrics and Gynaecology 95: 420–422, 1988
Kubo JH, Cody RJ. Enalapril, a rash, and captopril. Annals of Internal Medicine 100: 616, 1984
Lewis EJ. Angiotensin-converting enzyme inhibition: considerations regarding proteinuria. American Journal of Kidney Diseases 10 (Suppl. 1): 30–38, 1987
Lipworth BJ, McMurray JJ, Clark RA, Struthers AD. Development of persistent late onset asthma following treatment with captopril. European Respiratory Journal 2: 586–588, 1989
Madeddu P, Ena P, Dessi-Fulgheri P, Glorioso N, Cerimele D, et al. Captopril-induced proteinuria in hypertensive psoriatic patients. Nephron 44: 358–360, 1986
Maher JF. Clinicopathologic spectrum of drug nephrotoxicity. Advances in Internal Medicine 30: 295–316, 1984
Mallet L, Cooper JW, Thomas T. Bullous pemphigoid associated with captopril. DICP: Annals of Pharmacotherapy 23: 63, 1989
Mann J, Ritz E. Preservation of kidney function by use of converting-enzyme inhibitors for control of hypertension. Lancet 2: 622, 1987
Markkusse HM, Meyboom RHB. Gynecomastia associated with captopril. British Medical Journal 296: 1262, 1988
Maury M, Wakti H, Richer C, Francoual C, Relier JP, et al. Serum angiotensin I-converting enzyme activity in premature and full term infants. Biology of the Neonate 45: 102–104, 1984
McMurray J, Matthews DM. Consequences of fluid loss in patients treated with ACE inhibitors. Postgraduate Medical Journal 63: 385–387, 1987
Merck Sharpe & Dohme. Vasotec® (enalapril) product information package insert, West Point, Pennsylvania, 1988a
Merck Sharpe & Dohme. Prinvil® (lisinopril) product information package insert, West Point, Pennsylvania, 1988b
Michorowski B, Ceremuzynski L. The renin-angiotensin-aldo-sterone system and the clinical course of acute myocardial infarction. European Heart Journal 4: 259–264, 1983
Mirkin BL, Newman TJ. Efficacy and safety of captopril in treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 75: 1091–1100, 1985
Motel PJ. Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. Journal of the American Academy of Dermatology 23: 124–125, 1990
Nakamura Y, Yoshimoto K, Saima S. Gynecomastia induced by angiotensin converting enzyme inhibitor. British Medical Journal 300: 541, 1990
Navis GJ, deJong PE, deZeeuw D. Serum uric acid, ACE inhibitors, and natriuresis. Lancet 2: 156, 1985
Navis GJ, de Jong PE, Kallenberg CG, et al. Absence of cross-reactivity between captopril and enalapril. Lancet 1: 1017, 1984
Nicholls MG. Side effects and metabolic effects of converting-enzyme inhibitors. Clinical and Experimental Hypertension A9(2 & 3): 653–664, 1987
Nicholls MG, Gilchrist NL. Sulindac and cough induced by converting enzyme inhibitors. Lancet 1: 872, 1987
O’Hollaren MT, Porter GA. Angiotensin converting enzyme inhibitors and the allergist. Annals of Allergy 64: 503–506, 1990
Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): 527–530, 1989
Orfan N, Patterson R, Dykewicz MS. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. Journal of the American Medical Association 264: 1287–1289, 1990
Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. American Journal of Cardiology 60: 179–184, 1987
Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. American Journal of Cardiology 57: 347–348, 1986
Packer M, Lee WH, Kesler PD, Medina N, Yushak M, et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology 10: 837–844, 1987a
Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Annals of Internal Medicine 106: 346–354, 1987b
Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. New England Journal of Medicine 315: 847–853, 1986
Parfrey PS, Clement M, Vandenburg MJ, Wright P. Captopril induced pemphigus. British Medical Journal 194: 281, 1980
Patterson JF. Depression associated with enalapril. Southern Medical Journal 82: 402–403, 1989
Puppin D, Rybojad M, De La Chapelle C, Morel P. Kaposi’s sarcoma associated with captopril. Lancet 336: 1251–1252, 1990
Rosa FW, Bosco LA, Graham CF, Milstien JB, Dreis M, et al. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstetrics-Gynaecology 74: 371–374, 1989
Rosenfeld JB, Zabludowski J. The renin-angiotensin system, the kidney, and hypertension. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): S22–S26, 1989
Rotmensch HH, Vlasses PH, Ferguson RK. Resolution of captopril-induced rash after substitution of enalapril. Pharmacotherapy 3: 131–133, 1983
Rotmensch HH, Vlasses PH, Ferguson RK. Angiotensin-converting enzyme inhibitors. Medical Clinics of North America 72: 399–425, 1988
Ruocco V, deLuca M, Pisani M, deAngelis E, Vitale O, et al. Pemphigus provoked by d-penicillamine: an experimental approach using in vitro tissue culture. Dermatologica 164: 236–248, 1982
Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S99–S107, 1987
Schubiger G, Flury G. Enalapril for pregnancy induced hypertension: acute renal failure in a neonate. Annals of Internal Medicine 108: 214–216, 1988
Seidman MD, Lewandowski CA, Sarpa JR, Potesta E, Schweitzer VG. Angioedema related to angiotensin-converting enzyme inhibitors. Otolaryngology, Head and Neck Surgery 102: 727–731, 1990
Simon G, Marioka S, Snyder DK, Cohn JN. Increased renal plasma flow in long-term enalapril treatment of hypertension. Clinical Pharmacology and Therapeutics 34: 459–465, 1983
Slater FE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. Journal of the American Medical Association 260: 967–970, 1988
Squibb ER & Sons. Capoten® (captopril) product information package insert, Princeton, New Jersey, 1988
Stine S, Yang HY, Costa E. Intraventricular captopril inhibits in situ metabolism of enkephalin and naltrexone sensitive analgesia. Pharmacologist 21: 197, 1979
Stoller JK, Mehta AC, Vidt DG. Captopril-induced cough. Chest 93: 659–661, 1988
Stumpe KO, Kolloch R, Overlack A. Captopril and enalapril: evaluation of therapeutic efficacy and safety. Practical Cardiology 10: 111–124, 1984
Suarez M, Ho PWL, Johnson ES, Perez G. Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy. American Journal of Medicine 81: 336–349, 1986
Sugiyama E, Iwats M, Yamashita N, Yoshikawa T, Maruyama M, et al. Immunosuppression by captopril in vitro: inhibition of human natural killer activity by copper-dependent generation of hydrogen peroxide. Japanese Journal of Medicine 25: 149–154, 1986
Sullivan PA, Kelleher M, Twomey M, Dineen M. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension. Journal of Hypertension 3: 359–363, 1985
Swartz SL, Williams GH. Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology 49: 1405–1409, 1982
Tabibian N, Alpert L, Alpert E. Captopril-induced liver dysfunction. American Journal of Medicine 80: 1173–1175, 1987
Town GI, Hallwright GP, Maling TJB, O’Donnell TV. Angiotensin converting enzyme inhibitors and cough. New Zealand Medical Journal 100: 161–163, 1987
Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. Journal of Pediatrics 112: 295–298, 1988
Ujhelyi MR, Ferguson RK, Vlases PH. Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy 9: 351–362, 1989
Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low dose captopril in the treatment of mild to moderate hypertension. Hypertension 5 (Suppl. 3): 319–344, 1983
Vlasses PH, Ferguson RK, Chatterjee K. Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure. Pharmacotherapy 2: 1–17, 1982
Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. American Journal of Medicine 84 (Suppl. 4A): 16–23, 1988
Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5 (Suppl. III): 132–138, 1983
Weinberger MH, Yu PL, Perkins BJ. Renin in hypertension: further evidence for a vasculotoxic role. Clinical Research 21: 458, 1973
Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption — a possible mechanism: cutaneous kinin potentiation. Archives of Dermatology 116: 902–905, 1980
Wood SM, Mann RD, Rawlins MD. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. British Medical Journal 294: 91–92, 1987
Zubenko GS, Nixon RA. Mood elevating effect of captopril in depressed patients. American Journal of Psychiatry 141: 110–111, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parish, R.C., Miller, L.J. Adverse Effects of Angiotensin Converting Enzyme (ACE) Inhibitors. Drug-Safety 7, 14–31 (1992). https://doi.org/10.2165/00002018-199207010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199207010-00004